XTX Topco Ltd Has $1.60 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Key Points

• XTX Topco Ltd increased its stake in Amgen Inc. by 118.6%, owning 5,127 shares valued at approximately $1.6 million following the purchase of additional shares in the first quarter.
• A number of other hedge funds also raised their stakes in Amgen, with KPP Advisory Services LLC increasing its stake by 87.1%, bringing its total to 5,833 shares valued at $1.82 million.
• Amgen recently reported earnings of $4.90 EPS, surpassing the consensus estimate by $0.72, with revenue of $8.15 billion during the quarter, which shows a 9.4% year-over-year increase.

XTX Topco Ltd lifted its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 118.6% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,127 shares of the medical research company's stock after buying an additional 2,782 shares during the period. XTX Topco Ltd's holdings in Amgen were worth $1,597,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Pinney & Scofield Inc. purchased a new position in shares of Amgen during the fourth quarter valued at $26,000. First Pacific Financial grew its holdings in shares of Amgen by 304.5% during the first quarter. First Pacific Financial now owns 89 shares of the medical research company's stock valued at $28,000 after buying an additional 67 shares in the last quarter. Ritter Daniher Financial Advisory LLC DE grew its holdings in shares of Amgen by 66.2% during the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after buying an additional 51 shares in the last quarter. Heck Capital Advisors LLC purchased a new position in shares of Amgen during the fourth quarter valued at $36,000. Finally, Legacy Investment Solutions LLC grew its holdings in shares of Amgen by 46.9% during the fourth quarter. Legacy Investment Solutions LLC now owns 141 shares of the medical research company's stock valued at $37,000 after buying an additional 45 shares in the last quarter. Institutional investors own 76.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on AMGN. UBS Group lifted their price objective on Amgen from $315.00 to $326.00 and gave the company a "neutral" rating in a research report on Monday, July 21st. Cantor Fitzgerald reissued a "neutral" rating and set a $305.00 price objective on shares of Amgen in a research report on Tuesday, June 24th. Wall Street Zen raised Amgen from a "buy" rating to a "strong-buy" rating in a research report on Sunday, May 18th. Guggenheim began coverage on Amgen in a research report on Tuesday, May 20th. They set a "neutral" rating and a $288.00 price objective for the company. Finally, Morgan Stanley reissued an "equal weight" rating on shares of Amgen in a research report on Friday, May 2nd. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $307.27.

Insider Buying and Selling

In related news, SVP Rachna Khosla sold 1,500 shares of the stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total transaction of $434,520.00. Following the sale, the senior vice president directly owned 8,162 shares in the company, valued at $2,364,368.16. This represents a 15.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.76% of the stock is currently owned by company insiders.

Amgen Price Performance

Shares of AMGN stock traded up $1.78 during trading hours on Friday, hitting $296.88. The company had a trading volume of 2,410,860 shares, compared to its average volume of 1,708,073. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $339.17. The firm has a market capitalization of $159.63 billion, a price-to-earnings ratio of 27.09, a PEG ratio of 2.57 and a beta of 0.49. The firm's fifty day moving average is $292.04 and its 200 day moving average is $292.03. The company has a debt-to-equity ratio of 8.70, a quick ratio of 0.88 and a current ratio of 1.17.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.72. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The company had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. During the same period in the prior year, the company posted $3.96 EPS. The company's revenue was up 9.4% compared to the same quarter last year. On average, sell-side analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 12th. Investors of record on Friday, August 22nd will be given a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.2%. Amgen's dividend payout ratio (DPR) is presently 86.86%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.